$NXTC News

What's Going On With NextCure Stock Wednesday?

NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma Transcript

NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma - Slideshow

NextCure, Simcere Zaiming Pharmaceutical Present Phase 1 Dose Escalation Data For SIM0505 At American Society For Clinical Oncology With Proprietary Topoisomerase 1 Inhibitor Payload

LUCID CAPITAL MARKETS Initiates Coverage On NextCure with Buy Rating, Announces Price Target of $25

NextCure Q1 EPS $(1.87) Beats $(2.12) Estimate

NextCure And Simcere Zaiming Announce Phase 1 Data For SIM0505 In Treatment Of Solid Tumors Will Be Presented At ASCO 2026

NextCure's SIM0505 Receives FDA Fast Track For Platinum-Resistant Ovarian Cancer, Phase 1 Data To Be Presented At ASCO 2026

NextCure Q4 EPS $(0.81) Beats $(2.42) Estimate

NextCure Shares Update on Cancer Drug Trials, Cash Runway Extends Into 2027

NextCure Files For Offering Of Up To 2.52M Common Shares By Selling Stockholders

NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference

NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts

NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules

NextCure shares are trading higher after the company announced a $21.5 million private placement.

NextCure shares are trading higher after the company announced a $21.5 million private placement.

NextCure Announces $21.5 Private Placement For Purchase And Sale Of 2,523,477 Shares At $8.52/Share

Does NextCure (NXTC) Have the Potential to Rally 107.88% as Wall Street Analysts Expect?

Ladenburg Thalmann Upgrades NextCure to Buy, Announces $18 Price Target

NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results